- Home
- BG vs GMAB Comparison
BG vs GMAB Comparison
Compare BG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BG
- GMAB
- Stock Information
- Founded
- BG 1818
- GMAB 1999
- Country
- BG United States
- GMAB Denmark
- Employees
- BG N/A
- GMAB N/A
- Industry
- BG Packaged Foods
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BG Consumer Staples
- GMAB Health Care
- Exchange
- BG Nasdaq
- GMAB Nasdaq
- Market Cap
- BG 15.6B
- GMAB 15.4B
- IPO Year
- BG N/A
- GMAB N/A
- Fundamental
- Price
- BG $84.22
- GMAB $24.87
- Analyst Decision
- BG Buy
- GMAB Buy
- Analyst Count
- BG 5
- GMAB 6
- Target Price
- BG $87.00
- GMAB $37.60
- AVG Volume (30 Days)
- BG 2.0M
- GMAB 1.3M
- Earning Date
- BG 10-29-2025
- GMAB 08-07-2025
- Dividend Yield
- BG 3.32%
- GMAB N/A
- EPS Growth
- BG 12.90
- GMAB 77.72
- EPS
- BG 10.00
- GMAB 21.62
- Revenue
- BG $50,862,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- BG $1.40
- GMAB $22.68
- Revenue Next Year
- BG $5.63
- GMAB $15.85
- P/E Ratio
- BG $8.42
- GMAB $11.17
- Revenue Growth
- BG N/A
- GMAB 32.97
- 52 Week Low
- BG $67.40
- GMAB $17.24
- 52 Week High
- BG $101.81
- GMAB $27.93
- Technical
- Relative Strength Index (RSI)
- BG 57.17
- GMAB 65.71
- Support Level
- BG $83.92
- GMAB $24.28
- Resistance Level
- BG $88.51
- GMAB $25.25
- Average True Range (ATR)
- BG 2.12
- GMAB 0.37
- MACD
- BG 0.10
- GMAB 0.16
- Stochastic Oscillator
- BG 60.26
- GMAB 90.69
About BG Bunge Limited
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.